Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
Information source: M.D. Anderson Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Leukemia; Lymphoma
Intervention: Pentostatin (Drug); Tacrolimus (Drug); Methotrexate (Drug)
Phase: Phase 1/Phase 2
Status: Completed
Sponsored by: M.D. Anderson Cancer Center Official(s) and/or principal investigator(s): Marcos de Lima, MD, Principal Investigator, Affiliation: M.D. Anderson Cancer Center
Summary
Primary Objective:
1. To determine efficacy of escalating doses of pentostatin in combination with tacrolimus
and methotrexate for the prevention of acute graft-versus-host disease (GVHD) in the context
of unrelated donor and one antigen mismatched related donor transplantation.
Secondary Objectives:
1. To determine safety of escalating doses of pentostatin in combination with tacrolimus
and methotrexate.
2. To reduce the incidence of acute GVHD following transplants with unrelated donor to
40%.
3. To document blood levels of tacrolimus when combined with pentostatin.
Clinical Details
Official title: Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After Matched-Unrelated Donor Blood and Marrow Transplantation
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Number of Patients Without GVHD at 100 Days
Detailed description:
During the study, patients will have blood, urine, bone marrow, and X-ray exams done. These
exams are done to monitor the results of the transplantation. Blood tests will be done daily
while patients are hospitalized.
Patients in this study will receive chemotherapy and/or radiation to treat their malignancy
and prevent graft rejection. This is given before the infusion of donor cells.
Patients with myeloid leukemias may receive busulfan by vein (IV) for 4 days and
cyclophosphamide by vein for 2 days.
Patients with lymphoid malignancies may receive thiotepa by vein in one dose,
cyclophosphamide by vein for 2 days, and irradiation for 4 days.
Other chemotherapy treatments may be used before donor cell infusion.
IV injections will be given through a previously inserted catheter that extends into the
vena cava (a large chest vein).
Patients will be randomly picked (as in the toss of a coin) to receive one of five different
treatments. This is done to learn the benefit of pentostatin treatment and the appropriate
dose. Four of the treatments will use different dose schedules of pentostatin. The fifth
treatment group will receive no pentostatin at all. All patients receive tacrolimus and
methotrexate.
Pentostatin will be given by vein in 4 doses during the first month after transplant.
Tacrolimus (FK506) will be given by vein or mouth for 6 months. Methotrexate will be given
by vein for 3 doses in the first week after transplant.
Patients will receive blood and platelet transfusions after the transplant. The number of
transfusions will depend on how quickly the blood cell counts return to a normal range.
Patients will remain in the hospital for about 4-6 weeks and in the Houston area for 100
days after the transplant.
This is an investigational study. All of the study drugs are commercially available.
Pentostatin will not be used for GVHD prevention outside of this study. A total of 150
patients will take part in this study.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Patients receiving allogeneic hematopoietic transplants from an unrelated donor or
one antigen mismatched related donors.
2. Patients with AML, ALL, Hodgkin's disease, MDS (including CMML), CML in late chronic
or accelerated phase or in blast crisis, and lymphoma in first or later relapses.
3. Patients must have bilirubin < 1. 5 mg/dL, DLCO > 50% predicted, LVEF > 45% and
performance status 0 or 1.
4. Candidates must have a creatinine level < 1. 5 mg/dL or a calculated creatinine
clearance > 60 ml/min.
Exclusion Criteria:
1. HIV seropositivity
2. Uncontrolled infection
3. Pregnancy
4. Candidates should not have received chemotherapy other than hydroxyurea or Gleevec
for at least 3 weeks prior to treatment. Maintenance therapy with oral chemotherapy
is acceptable. Treatment day is defined as transplant day +8, which is the date of
first dose of pentostatin.
5. Diagnosis of myelofibrosis.
Locations and Contacts
U.T.M.D. Anderson Cancer Center, Houston, Texas 77030, United States
Additional Information
UT MD Anderson Cancer Center website
Starting date: September 2000
Last updated: April 6, 2015
|